

40th PLENARY MEETING OF THE SCIENTIFIC PANEL ON DIETETIC PRODUCTS, NUTRITION AND ALLERGIES

Meeting dates: 11-13 May 2011
Venue: EFSA, Largo N. Palli 5/a, Parma, 43121

Draft Agenda

#	Items
1	Welcome, apologies for absence
2	Adoption of the agenda of this Plenary meeting & the minutes of the previous Plenary meeting
3	Declarations of interest
4	Feedback from EFSA Scientific Committee and other EFSA Panels, and general information from EFSA
5	Feedback from the Commission on matters relating to the Panel
6	Meeting dates for 2012
7	New requests
8	Novel Foods - <i>For discussion/possible adoption</i>
	8.1 "Safety of Glavonoid[®]"
9	General issues on health claims evaluations
	9.1. Finalisation of Article 13 list claims
	9.2. Update on Article 13(5) and 14 applications
	9.3. Remaining issues from adopted Art. 13 opinions at last Panel
	9.4. Administrative amendments to the scientific and technical guidance for the preparation and presentation of the application for authorisation of a health claim - <i>For discussion/possible adoption</i>
	9.5. Draft guidance requirements for health claims related to neurological and psychological functions - <i>For discussion/possible endorsement for release for public consultation</i>

- 10 **Applications pursuant to Article 14/13(5) of Regulation (EC) No 1924/2006 - *For discussion/ possible adoption***
- 10.1 “Biscuits for breakfast” and “appearance in the blood circulation of exogenous glucose from biscuits consumed for breakfast that is moderate and stable throughout the morning”
 - 10.2 “*Lactobacillus GG*” and “improves body’s resistance”
 - 10.3 “Peptides isoleucyl-prolyl-proline (IPP) and valyl-prolyl-proline (VPP)” and “helps to maintain normal blood pressure”
 - 10.4 “KOT products” and “reduction of adipocyte size at the abdominal level”
 - 10.5 Trans free spreadable fats rich in unsaturated fatty acids and reduction of LDL-cholesterol concentrations
 - 10.6 Zinc and “prevention of bad breath”
 - 10.7 Collagen hydrolysate and “maintenance of joint health”
 - 10.8 “Combination of bacterial strains *Bifidobacterium bifidum*, *Bifidobacterium infantis*, *Lactobacillus acidophilus* and reduction of the rate of immunity decrease”
 - 10.9 “Combination of bacterial strains *Bifidobacterium bifidum*, *Bifidobacterium infantis*, *Lactobacillus acidophilus* and reduction of the damage extent of intestinal microflora”
 - 10.10 “Beta-Palmitate” and “increased calcium absorption”
- 11 **Draft Art. 13 opinions - *For discussion/possible adoption***
- Related to**
- 11.1 Oat bran fibre
 - 11.2 Fructose
 - 11.3 Creatine
 - 11.4 Creatine + Beta alanine
 - 11.5 *Monascus purpureus* (red yeast rice)
 - 11.6 LA + GLA
 - 11.7 Carbonates and citrates
 - 11.8 Cranberries
 - 11.9 Soy isoflavones
 - 11.10 Lactose
- 12 **Dietary reference values for protein - *For discussion/possible endorsement for release for public consultation***
- 13 **Any other business**